Mesenchymal Tumor Of The Gastrointestinal Tract drugs in development by stages, target, MoA, RoA, molecule type and key players, 2023

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mesenchymal Tumor Of The Gastrointestinal Tract and features dormant and discontinued products.

GlobalData tracks 75 drugs in development for Mesenchymal Tumor Of The Gastrointestinal Tract by 59 companies/universities/institutes. The top development phase for Mesenchymal Tumor Of The Gastrointestinal Tract is phase ii with 24 drugs in that stage. The Mesenchymal Tumor Of The Gastrointestinal Tract pipeline has 71 drugs in development by companies and four by universities/ institutes. Some of the companies in the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline products market are: Novartis, Deciphera Pharmaceuticals and Bayer.

The key targets in the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline products market include Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1), Platelet Derived Growth Factor Receptor Alpha (Alpha Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member A or Platelet Derived Growth Factor Receptor 2 or CD140a or PDGFRA or EC 2.7.10.1), and Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1).

The key mechanisms of action in the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline product include Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 c Kit or CD117 or KIT or EC 2.7.10.1) Inhibitor with 17 drugs in Filing rejected/Withdrawn. The Mesenchymal Tumor Of The Gastrointestinal Tract pipeline products include nine routes of administration with the top ROA being Oral and ten key molecule types in the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline products market including Small Molecule, and Monoclonal Antibody.

Mesenchymal Tumor Of The Gastrointestinal Tract overview

Mesenchymal tumors represent a heterogenous group of neoplasms that include malignant, intermediate malignancy, and benign entities. Sarcomas are extremely rare, accounting for only 1% of malignancies in adults and up to 10-15% of malignancies in the paediatric population. They are characterized by a global incidence of 30-50 cases per million person-years and show a wide anatomic distribution. Rarely, mesenchymal lesions may occur in the gastrointestinal (GI) tract. Some of these entities occur almost exclusively in the GI tract, whereas other subtypes, when located in the GI tract, may assume distinct morphological features. The majority of sarcomas of the GI tract are represented by gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors in the stomach as well as in the small bowel. GIST represents a distinctive mesenchymal neoplasm sharing immunomorphologic features with the interstitial cell of Cajal. It exhibits an exclusive tropism for the GI tract.

For a complete picture of Mesenchymal Tumor Of The Gastrointestinal Tract’s pipeline drug market, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.